Antibody-based Therapies May Trigger Brain Inflammation

Antibody-based Therapies May Trigger Brain Inflammation

291174

Antibody-based Therapies May Trigger Brain Inflammation

New research suggests that brain inflammation is the likely reason antibody-based therapies are ineffective in clinical trials for people with Parkinson’s and Alzheimer’s diseases. The findings show that the binding of the antibody to its target protein — in the case of Parkinson’s disease the misfolded alpha-synuclein — trigger a pro-inflammatory state in human microglial cells, which are the immune cells of the central nervous system (CNS). “Our findings provide a possible explanation for why…

You must be logged in to read/download the full post.